Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

0(0%)

Results Posted

200%(2 trials)

Terminated

3(60%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(4)

Detailed Status

Terminated3

Withdrawn1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

terminated360%

withdrawn120%

completed120%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_1

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT05708924

completedphase_1

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

NCT04714372

withdrawnphase_1

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

NCT05700630

terminatedphase_1

FT538 in Subjects With Advanced Hematologic Malignancies

NCT04614636

terminatedphase_1

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05069935

Clinical Trials (5)

Showing 5 of 5 trials

NCT05708924Phase 1

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Terminated

NCT04714372Phase 1

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Completed

NCT05700630Phase 1

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Withdrawn

NCT04614636Phase 1

FT538 in Subjects With Advanced Hematologic Malignancies

Terminated

NCT05069935Phase 1

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5